By Rédaction Africa Links 24 with Damian Garde
Published on 2024-01-23 14:41:40
To stay informed about the latest developments in the fast-paced world of biotechnology, there’s no better way than signing up for our biotech newsletter. Here’s a quick overview of some of the most significant events in the biotech industry. Sanofi’s recent acquisition of Inhibrx for up to $2.2 billion, with a focus on an experimental drug called INBRX-101, marks a significant move in the field. Additionally, the FDA has recommended new safety warnings for CAR-T cancer therapies due to cases of secondary cancers post-treatment. Furthermore, Gilead Sciences’ struggles with its late-stage lung cancer study have raised investor concerns, leading to a significant drop in its market value. The recent J.P. Morgan Healthcare Conference has had a positive impact on biotech stocks, leading to optimism for the coming year. On the political front, the pharmaceutical lobby’s opposition to the Biden administration’s drug pricing policy may actually play in the president’s favor by raising awareness of the popular idea of Medicare negotiation of drug prices. Another significant development involves the messy transition at Evotec, a German biotech company, following the departure of its CEO for personal reasons, only to be terminated later due to failure to report stock trades. In addition to these events, there are several other interesting reads in the biotech industry that you might want to explore. Overall, the diverse and dynamic landscape of biotech continues to present both opportunities and challenges. If you’re interested in staying up-to-date with more insights and analysis on the biotech industry, we invite you to join our upcoming biotech newsletter.
Read the original article on Africa Health News
